The small intestine provides a big opportunity to transform medicine
We are discovering and developing a new class of orally delivered medicines that act on cells in the small intestine with systemic therapeutic effects. Cells in the small intestine play a central role in governing the immune, metabolic, and neurological systems.
Our IP estate provides several layers of protection for our therapies. We have multiple issued patents and many pending patent applications covering our product candidates and platform technology. Our current patent estate is expected, based on the particular patent or application, to provide patent protection that will expire between the late 2020s and early 2040s.